Citations

Clear

9 citation(s) found for "Zhu, Qian".

USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization
Liu, Jiaqi , Zhu, Qian , Zhang, Yixin , Chen, Yuping , Wang, Kaikai , Lou, Zhenkun , Yuan, Jian

Mayo Clinic

CNS Neuroscience & Therapeutics | April 22, 2024 | Volume: 30 | Issue: 4 | Pages: No page available

10.1111/cns.14711 | PMID 38644551 Get It

AbstractObjectiveTo elucidate the relationship between USP19 and O(6)‐methylguanine‐DNA methyltransferase (MGMT) after temozolomide treatment in glioblastoma (GBM) patients with chemotherapy resistance.MethodsScreening the deubiquitinase pannel and identifying the deubiquitinase directly interacts with and deubiquitination MGMT. Deubiquitination assay to confirm USP19 deubiquitinates MGMT. The colony formation and tumor growth study in xenograft assess USP19 affects the GBM sensitive to TMZ was performed by T98G, LN18, U251, and U87 cell lines. Immunohistochemistry staining and survival analysis were performed to explore how USP19 is correlated to MGMT in GBM clinical management.ResultsUSP19 removes the ubiquitination of MGMT to facilitate the DNA methylation damage repair. Depletion of USP19 results in the glioblastoma cell sensitivity to temozolomide, which can be rescued by overexpressing MGMT. USP19 is overexpressed in glioblastoma patient samples, which positively correlates with the level of MGMT protein and poor prognosis in these patients.ConclusionThe regulation of MGMT ubiquitination by USP19 plays a critical role in DNA methylation damage repair and GBM patients’ temozolomide chemotherapy response.
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Yang, Qifan, Zeng, Xiangyu , Wang, Manxiang , Tu, Xinyi , Wei, Ting , Xie, Wenzhuan , Guo, Qiang , Kloeber, Jake A. , Cao, Yueyu, Guo, Guijie , Zhou, Qin , Huang, Jinzhou , Zhang, Kai , Luo, Kuntian, Kim, Wootae , Hou, Jing , Shi, Yu , Zhu, Qian , Hu, Sheng , Yue, Junqiu , Pi, Guoliang , Kloeber, Jake A , Liu, Li , Kim, Wootae , Zhu, Qian , Wei, Ting , Zeng, Xiangyu , Zhang, Yong , Dong, Shuang , Yang, Bin , Zhang, Chao , Zhao, Fei Linda , Liu, Li , Wang, Mingwei , Yin, Ping , Deng, Min , Chen, Lifeng , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Cancer Discovery | June 7, 2021 | Volume: 11 | Issue: 11 | Pages: 2726-2737

10.1158/2159-8290.cd-20-1500 | PMID 34099454 Get It

Abstract Immune checkpoint blockade (ICB) has revolutionized cancer therapy. However, the response of patients to ICB is difficult to predict. Here, we examined 81 patients with lung cancer under ICB treatment and found that patients with MET amplification were resistant to ICB and had a poor progression-free survival. Tumors with MET amplifications had significantly decreased STING levels and antitumor T-cell infiltration. Furthermore, we performed deep single-cell RNA sequencing on more than 20,000 single immune cells and identified an immunosuppressive signature with increased subsets of XIST- and CD96-positive exhausted natural killer (NK) cells and decreased CD8+ T-cell and NK-cell populations in patients with MET amplification. Mechanistically, we found that oncogenic MET signaling induces phosphorylation of UPF1 and downregulates tumor cell STING expression via modulation of the 3′-UTR length of STING by UPF1. Decreased efficiency of ICB by MET amplification can be overcome by inhibiting MET. Significance: We suggest that the combination of MET inhibitor together with ICB will overcome ICB resistance induced by MET amplification. Our report reveals much-needed information that will benefit the treatment of patients with primary MET amplification or EGFR–tyrosine kinase inhibitor resistant-related MET amplification. This article is highlighted in the In This Issue feature, p. 2659
DOCK7 protects against replication stress by promoting RPA stability on chromatin
Gao, Ming , Guo, Guijie , Huang, Jinzhou , Hou, Xiaonan , Ham, Hyoungjun , Kim, Wootae , Tu, Xinyi , Zhou, Qin , Zhang, Chao , Zhu, Qian , Liu, Jiaqi , Xu, Zhijie , Luo, Kuntian, Weroha, S. John , Billadeau, Daniel D. , Yan, Yuanliang, Weroha, John, Kim, Wootae , Xu, Zhijie , Zhao, Fei , Yan, Yuanliang , Yin, Ping , Deng, Min , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Nucleic Acids Research | March 2, 2021 | Volume: 49 | Issue: 6 | Pages: 3322-3337

10.1093/nar/gkab134 | PMID 33704464 Get It

Abstract RPA is a critical factor for DNA replication and replication stress response. Surprisingly, we found that chromatin RPA stability is tightly regulated. We report that the GDP/GTP exchange factor DOCK7 acts as a critical replication stress regulator to promote RPA stability on chromatin. DOCK7 is phosphorylated by ATR and then recruited by MDC1 to the chromatin and replication fork during replication stress. DOCK7-mediated Rac1/Cdc42 activation leads to the activation of PAK1, which subsequently phosphorylates RPA1 at S135 and T180 to stabilize chromatin-loaded RPA1 and ensure proper replication stress response. Moreover, DOCK7 is overexpressed in ovarian cancer and depleting DOCK7 sensitizes cancer cells to camptothecin. Taken together, our results highlight a novel role for DOCK7 in regulation of the replication stress response and highlight potential therapeutic targets to overcome chemoresistance in cancer.
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining
Zhou, Qin , Howard, Michelle E. , Tu, Xinyi , Zhu, Qian , Denbeigh, Janet M. , Remmes, Nicholas B. , Herman, Michael , Beltran, Chris , Greipp, Patricia T. , Wang, Liewei , Johnson, Neil , Mutter, Robert W. , Herman, Michael G., Beltran, Chris J., Boughey, JC , Beltran, Chris J , Greipp, Patricia T , Yuan, Jian , Boughey, Judy C. , Goetz, Matthew P. , Sarkaria, Jann N. , Lou, Zhenkun

Mayo Clinic

Cancer Research | February 17, 2021 | Volume: 81 | Issue: 12 | Pages: 3333-3346

10.1158/0008-5472.can-20-2960 | PMID 33597272 Get It

Abstract Proton Bragg peak irradiation has a higher ionizing density than conventional photon irradiation or the entrance of the proton beam profile. Whether targeting the DNA damage response (DDR) could enhance vulnerability to the distinct pattern of damage induced by proton Bragg peak irradiation is currently unknown. Here, we performed genetic or pharmacologic manipulation of key DDR elements and evaluated DNA damage signaling, DNA repair, and tumor control in cell lines and xenografts treated with the same physical dose across a radiotherapy linear energy transfer spectrum. Radiotherapy consisted of 6 MV photons and the entrance beam or Bragg peak of a 76.8 MeV spot scanning proton beam. More complex DNA double-strand breaks (DSB) induced by Bragg peak proton irradiation preferentially underwent resection and engaged homologous recombination (HR) machinery. Unexpectedly, the ataxia-telangiectasia mutated (ATM) inhibitor, AZD0156, but not an inhibitor of ATM and Rad3-related, rendered cells hypersensitive to more densely ionizing proton Bragg peak irradiation. ATM inhibition blocked resection and shunted more DSBs to processing by toxic ligation through nonhomologous end-joining, whereas loss of DNA ligation via XRCC4 or Lig4 knockdown rescued resection and abolished the enhanced Bragg peak cell killing. Proton Bragg peak monotherapy selectively sensitized cell lines and tumor xenografts with inherent HR defects, and the repair defect induced by ATM inhibitor coadministration showed enhanced efficacy in HR-proficient models. In summary, inherent defects in HR or administration of an ATM inhibitor in HR-proficient tumors selectively enhances the relative biological effectiveness of proton Bragg peak irradiation. Significance: Coadministration of an ATM inhibitor rewires DNA repair machinery to render cancer cells uniquely hypersensitive to DNA damage induced by the proton Bragg peak, which is characterized by higher density ionization. See related commentary by Nickoloff, p. 3156
The deubiquitinase USP36 Regulates DNA replication stress and confers therapeutic resistance through PrimPol stabilization
Xu, Zhijie , Huang, Jinzhou , Guo, Guijie , Gao, Ming , Kim, Wootae , Zeng, Xiangyu , Kloeber, Jake A. , Zhu, Qian , Luo, Kuntian, Yan, Yuanliang, Kloeber, Jake A , Kim, Wootae , Xu, Zhijie , Zeng, Xiangyu , Yan, Yuanliang , Zhao, Fei , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Nucleic Acids Research | October 29, 2020 | Volume: 48 | Issue: 22 | Pages: 12711-12726

10.1093/nar/gkaa1090 | PMID 33237263 Get It

Abstract PrimPol has been recently identified as a DNA damage tolerant polymerase that plays an important role in replication stress response. However, the regulatory mechanisms of PrimPol are not well defined. In this study, we identify that the deubiquitinase USP36 interferes with degradation of PrimPol to regulate the replication stress response. Mechanistically, USP36 is deubiquitinated following DNA replication stress, which in turn facilitates its upregulation and interaction with PrimPol. USP36 deubiquitinates K29-linked polyubiquitination of PrimPol and increases its protein stability. Depletion of USP36 results in replication stress-related defects and elevates cell sensitivity to DNA-damage agents, such as cisplatin and olaparib. Moreover, USP36 expression positively correlates with the level of PrimPol protein and poor prognosis in patient samples. These findings indicate that the regulation of PrimPol K29-linked ubiquitination by USP36 plays a critical role in DNA replication stress and chemotherapy response.
Desiderata for computable representations of electronic health records-driven phenotype algorithms
Mo, Huan , Thompson, William K. , Rasmussen, Luke V. , Pacheco, Jennifer A. , Jiang, Guoqian , Kiefer, Richard C. , Zhu, Qian , Xu, Jie , Montague, Enid , Mentch, Frank , Ni, Yizhao , Wehbe, Firas , Peissig, Peggy , Tromp, Gerard , Larson, Eric B. , Pathak, Jyotishman , Denny, Joshua C. , Speltz, Peter, Jarvik, Gail P. , Bejan, Cosmin A, Borthwick, Kenneth M., Kitchner, Terrie, Roden, Dan M. , Bejan, Cosmin A. , Kiefer, Richard, Carrell, David , Lingren, Todd , Chute, Christopher G. , Kho, Abel , Bejan, Cosmin A, Williams, Marc S , Roden, Dan M. , Harris, Paul A. , Denny, Joshua C , Jarvik, Gail P , Rasmussen, Luke V , Pacheco, Jennifer A

Mayo Clinic

Journal of the American Medical Informatics Association | September 6, 2015 | Volume: 22 | Issue: 6 | Pages: 1220-1230

10.1093/jamia/ocv112 | PMID 26342218 Get It

AbstractBackground Electronic health records (EHRs) are increasingly used for clinical and translational research through the creation of phenotype algorithms. Currently, phenotype algorithms are most commonly represented as noncomputable descriptive documents and knowledge artifacts that detail the protocols for querying diagnoses, symptoms, procedures, medications, and/or text-driven medical concepts, and are primarily meant for human comprehension. We present desiderata for developing a computable phenotype representation model (PheRM).Methods A team of clinicians and informaticians reviewed common features for multisite phenotype algorithms published in PheKB.org and existing phenotype representation platforms. We also evaluated well-known diagnostic criteria and clinical decision-making guidelines to encompass a broader category of algorithms.Results We propose 10 desired characteristics for a flexible, computable PheRM: (1) structure clinical data into queryable forms; (2) recommend use of a common data model, but also support customization for the variability and availability of EHR data among sites; (3) support both human-readable and computable representations of phenotype algorithms; (4) implement set operations and relational algebra for modeling phenotype algorithms; (5) represent phenotype criteria with structured rules; (6) support defining temporal relations between events; (7) use standardized terminologies and ontologies, and facilitate reuse of value sets; (8) define representations for text searching and natural language processing; (9) provide interfaces for external software algorithms; and (10) maintain backward compatibility.Conclusion A computable PheRM is needed for true phenotype portability and reliability across different EHR products and healthcare systems. These desiderata are a guide to inform the establishment and evolution of EHR phenotype algorithm authoring platforms and languages.
Review and evaluation of electronic health records-driven phenotype algorithm authoring tools for clinical and translational research
Xu, Jie , Rasmussen, Luke V. , Shaw, Pamela L , Jiang, Guoqian , Kiefer, Richard C. , Mo, Huan , Pacheco, Jennifer A. , Speltz, Peter, Zhu, Qian , Denny, Joshua C. , Pathak, Jyotishman , Thompson, William K. , Montague, Enid , Denny, Joshua C , Rasmussen, Luke V , Pacheco, Jennifer A

Mayo Clinic

Journal of the American Medical Informatics Association | July 30, 2015 | Volume: 22 | Issue: 6 | Pages: 1251-1260

10.1093/jamia/ocv070 | PMID 26224336 Get It

Abstract Objective To review and evaluate available software tools for electronic health record–driven phenotype authoring in order to identify gaps and needs for future development. Materials and Methods Candidate phenotype authoring tools were identified through (1) literature search in four publication databases (PubMed, Embase, Web of Science, and Scopus) and (2) a web search. A collection of tools was compiled and reviewed after the searches. A survey was designed and distributed to the developers of the reviewed tools to discover their functionalities and features. Results Twenty-four different phenotype authoring tools were identified and reviewed. Developers of 16 of these identified tools completed the evaluation survey (67% response rate). The surveyed tools showed commonalities but also varied in their capabilities in algorithm representation, logic functions, data support and software extensibility, search functions, user interface, and data outputs. Discussion Positive trends identified in the evaluation included: algorithms can be represented in both computable and human readable formats; and most tools offer a web interface for easy access. However, issues were also identified: many tools were lacking advanced logic functions for authoring complex algorithms; the ability to construct queries that leveraged un-structured data was not widely implemented; and many tools had limited support for plug-ins or external analytic software. Conclusions Existing phenotype authoring tools could enable clinical researchers to work with electronic health record data more efficiently, but gaps still exist in terms of the functionalities of such tools. The present work can serve as a reference point for the future development of similar tools.
EXPLORING THE PHARMACOGENOMICS KNOWLEDGE BASE (PHARMGKB) FOR REPOSITIONING BREAST CANCER DRUGS BY LEVERAGING WEB ONTOLOGY LANGUAGE (OWL) AND CHEMINFORMATICS APPROACHES
Shen, Feichen , Zhu, Qian , Tao, Cui , Chute, Christopher G.

Mayo Clinic

Biocomputing 2014 | November 18, 2013 | Volume: No volume available | Issue: No issue available | Pages: 172-182

10.1142/9789814583220_0017 Get It

INTEGRATING VA'S NDF-RT DRUG TERMINOLOGY WITH PHARMGKB: PRELIMINARY RESULTS
Pathak, Jyotishman , WEISS, LAURA C., Durski, Matthew J., Zhu, Qian , Freimuth, Robert R. , Chute, Christopher G.

Mayo Clinic

Biocomputing 2012 | December 9, 2011 | Volume: No volume available | Issue: No issue available | Pages: 400-409

10.1142/9789814366496_0039 Get It